DEA Extends Telehealth Prescribing for Opioid Addiction, ADHD Through December 31, 2025

Nov 18, 2024, 07:53 PM

Federal officials have announced a one-year extension of telehealth prescribing for controlled substances, including drugs for opioid addiction and ADHD, allowing health providers to continue offering these services through December 31, 2025. This decision marks the third extension of COVID-era telemedicine prescribing flexibilities, resolving a prolonged stalemate among policymakers. The Drug Enforcement Administration (DEA) confirmed the extension, which is expected to benefit both patients and telehealth providers, as it maintains access to necessary medications remotely. The announcement comes amid ongoing discussions about the future of telehealth regulations, with final rules anticipated from the incoming administration.